Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

The results of a new study in mice show that early exposure to certain bacteria and fungus can give the immune system a boost and reduce the risk of type 1 diabetes.

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.

Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.

The annual meeting of the Academy of Managed Care Pharmacy will take place in Houston from March 31 - April 3 at the George R. Brown Convention Center.

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.

Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) narrowed in the FAME 3 five-year follow-up study, but there were fewer myocardial infarctions and repeat revascularizations in the PCI group.

The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led follow-up care after acute coronary syndrome.

Here’s what you missed this week on Managed Healthcare Executive.

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and all-cause death.

The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior author.

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025.

The results are one of 10 from the FINEARTS-HF that are scheduled for presentation at the

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to bleeding risks.

In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.

Deploying virtual advanced practice providers requires clear roles and responsibilities in order for it to be effective and achieve measurable results.

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations.

The HHS secretary’s plans would create a new Administration for a Healthy America (AHA) subagency and slash the department’s workforce by 25%, including 3,500 full-time positions at the FDA.

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.

During last year’s enrollment period, millions of Medicare beneficiaries reviewed their coverage options and selected new Medicare plans for the 2025 calendar year due to changes including the plans being offered, increases in premiums and more, according to an eHealth analysis.